Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility.
Epoetin zeta was granted marketing authorization in October 2007 by the European Medicines Agency as a recombinant human erythropoietin erythropoiesis-stimulating agent to treat symptomatic anemia of renal origin in adult and pediatric patients on hemodialysis and adults on peritoneal dialysis, as well as for symptomatic renal anemia in adult patients with renal insufficiency not yet on dialysis. Currently, epoetin zeta can be administered either subcutaneously or intravenously to correct for hemoglobin concentrations ≤10 g/dL (6.2 mmol/L) or with dose adjustment to maintain hemoglobin levels at desired levels not in excess of 12 g/dL (7.5 mmol/L). This review article focuses on epoetin zeta indications in chronic kidney disease, its use in managing anemia of renal origin, and discusses its pharmacology and clinical utility.
Organizational Systems and Adult Health, University of Maryland School of Nursing, Baltimore, MD, USA.
Mary Lynn
ML
Davis-Ajami
South Carolina College of Pharmacy, University of South Carolina, Greenville, SC, USA.
Jun
J
Wu
Health Sciences and Human Services Library, University of Maryland, Baltimore, MD, USA.
Katherine
K
Downton
Health Sciences and Human Services Library, University of Maryland, Baltimore, MD, USA.
Emilie
E
Ludeman
Department of Clinical Pharmacy and Outcomes Science, South Carolina College of Pharmacy, University of South Carolina, Columbia, SC, USA.
Virginia
V
Noxon
Retacrit®; biosimilar; chronic kidney disease; epoetin alfa; erythropoiesis; renal anemia